These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 27013591)
21. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Tan DSW; Chong FT; Leong HS; Toh SY; Lau DP; Kwang XL; Zhang X; Sundaram GM; Tan GS; Chang MM; Chua BT; Lim WT; Tan EH; Ang MK; Lim TKH; Sampath P; Chowbay B; Skanderup AJ; DasGupta R; Iyer NG Nat Med; 2017 Oct; 23(10):1167-1175. PubMed ID: 28920960 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution. Xu J; Liu X; Yang S; Zhang X; Shi Y Asia Pac J Clin Oncol; 2017 Dec; 13(6):379-384. PubMed ID: 28276163 [TBL] [Abstract][Full Text] [Related]
23. Expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in Chinese patients with esophageal squamous cell carcinoma. Cui Y; Dong C; Wu BQ; Duan XC; Shi G; Gong M; Wang TY J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C44-8. PubMed ID: 26323923 [TBL] [Abstract][Full Text] [Related]
24. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma. Yang YL; Chu JY; Luo ML; Wu YP; Zhang Y; Feng YB; Shi ZZ; Xu X; Han YL; Cai Y; Dong JT; Zhan QM; Wu M; Wang MR Genes Chromosomes Cancer; 2008 Feb; 47(2):127-36. PubMed ID: 17990328 [TBL] [Abstract][Full Text] [Related]
25. Marked Response to Icotinib in Lung Squamous Cell Carcinoma with EGFR Wild-Type. Fan T; Zhou JY J Coll Physicians Surg Pak; 2018 Jun; 28(6):S120-S122. PubMed ID: 29866243 [TBL] [Abstract][Full Text] [Related]
26. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302 [TBL] [Abstract][Full Text] [Related]
27. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Itakura Y; Sasano H; Shiga C; Furukawa Y; Shiga K; Mori S; Nagura H Cancer; 1994 Aug; 74(3):795-804. PubMed ID: 8039107 [TBL] [Abstract][Full Text] [Related]
28. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613 [TBL] [Abstract][Full Text] [Related]
29. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes. Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808 [TBL] [Abstract][Full Text] [Related]
30. Diagnostic and predictive significance of serum microRNA-7 in esophageal squamous cell carcinoma. Dong W; Li B; Wang J; Song Y; Zhang Z; Fu C; Zhang P Oncol Rep; 2016 Mar; 35(3):1449-56. PubMed ID: 26708917 [TBL] [Abstract][Full Text] [Related]
31. Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study. Xu Y; Zheng Y; Sun X; Yu X; Gu J; Wu W; Zhang G; Hu J; Sun W; Mao W Oncotarget; 2015 Nov; 6(35):38429-39. PubMed ID: 26392415 [TBL] [Abstract][Full Text] [Related]
32. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. Zhao X; Zhu G; Chen H; Yang P; Li F; Du N J Cancer Res Ther; 2014 Nov; 10 Suppl():C155-9. PubMed ID: 25450275 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. Zhao X; Zhu G; Chen H; Yang P; Li F; Du N J Cancer Res Ther; 2016; 12(3):1127-1131. PubMed ID: 28054523 [TBL] [Abstract][Full Text] [Related]
35. Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib. Drenckhan A; Grob T; Dupree A; Dohrmann T; Mann O; Izbicki JR; Gros SJ Langenbecks Arch Surg; 2014 Oct; 399(7):879-88. PubMed ID: 25070024 [TBL] [Abstract][Full Text] [Related]
36. Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study. Liu R; Liu L; Zhao C; Bai Y; Zheng Y; Zhang S; Li N; Yang J; Fan Q; Wang X; Zeng S; Zhang Y; Zhang W; Zhuang Y; Kang N; Jiang Y; Sun H; Xu J BMC Gastroenterol; 2021 Oct; 21(1):398. PubMed ID: 34688250 [TBL] [Abstract][Full Text] [Related]
37. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma. Li Y; Fu L; Li JB; Qin Y; Zeng TT; Zhou J; Zeng ZL; Chen J; Cao TT; Ban X; Qian C; Cai Z; Xie D; Huang P; Guan XY Gastroenterology; 2014 Jun; 146(7):1701-13.e9. PubMed ID: 24561231 [TBL] [Abstract][Full Text] [Related]
38. Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling. Sun X; Xu Y; Wang Y; Chen Q; Liu L; Bao Y Med Sci Monit; 2018 May; 24():3193-3203. PubMed ID: 29763936 [TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma. Zhang W; Zhu H; Liu X; Wang Q; Zhang X; He J; Sun K; Liu X; Zhou Z; Xu N; Xiao Z Ann Thorac Surg; 2014 Aug; 98(2):513-9. PubMed ID: 24881860 [TBL] [Abstract][Full Text] [Related]
40. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma. Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]